People · Operator
Named in public records as an officer, director or promoter · active 2022–2022 · Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| T3D Therapeutics, Inc. | — | Pharmaceuticals | Series A | $30.0M | $70.9M | 2022 |
David Keim at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside David Keim on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Tom Mendell | 1 | 2 |
| John Didsbury | 1 | 1 |
| Barry Buzogany | 1 | 1 |
| John A. Golden | 1 | 1 |
| Donald Parker | 1 | 1 |
| John Golden | 1 | 1 |
| Charles Lineberry | 1 | 1 |
| Tom A. Mendell | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.